Annual EBITDA
$7.32 M
+$44.93 M+119.47%
01 December 2023
Summary:
Oramed Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently $7.32 million, with the most recent change of +$44.93 million (+119.47%) on 01 December 2023. During the last 3 years, it has risen by +$19.56 million (+159.84%). ORMP annual EBITDA is now at all-time high.ORMP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$3.04 M
-$14.19 M-127.23%
01 September 2024
Summary:
Oramed Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$3.04 million, with the most recent change of -$14.19 million (-127.23%) on 01 September 2024. Over the past year, it has dropped by -$17.60 million (-120.86%). ORMP quarterly EBITDA is now -120.86% below its all-time high of $14.56 million, reached on 01 December 2023.ORMP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$24.86 M
-$633.00 K-2.48%
01 September 2024
Summary:
Oramed Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $24.86 million, with the most recent change of -$633.00 thousand (-2.48%) on 01 September 2024. Over the past year, it has increased by +$17.54 million (+239.54%). ORMP TTM EBITDA is now -2.48% below its all-time high of $25.49 million, reached on 01 June 2024.ORMP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ORMP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -120.9% | +239.5% |
| 3 y3 years | +159.8% | +61.6% | +194.8% |
| 5 y5 years | +150.1% | -25.0% | +294.8% |
ORMP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +119.5% | -120.9% | +73.4% | -2.5% | +164.6% |
| 5 y | 5 years | at high | +119.5% | -120.9% | +73.4% | -2.5% | +164.6% |
| alltime | all time | at high | +119.5% | -120.9% | +73.4% | -2.5% | +164.6% |
Oramed Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.04 M(-127.2%) | $24.86 M(-2.5%) |
| June 2024 | - | $11.15 M(+411.1%) | $25.49 M(+94.9%) |
| Mar 2024 | - | $2.18 M(-85.0%) | $13.08 M(+78.6%) |
| Dec 2023 | $7.32 M(-119.5%) | $14.56 M(-705.7%) | $7.32 M(-145.9%) |
| Sept 2023 | - | -$2.40 M(+90.6%) | -$15.96 M(-22.9%) |
| June 2023 | - | -$1.26 M(-64.7%) | -$20.69 M(-32.9%) |
| Mar 2023 | - | -$3.57 M(-59.0%) | -$30.83 M(-19.9%) |
| Dec 2022 | -$37.61 M(+207.4%) | -$8.72 M(+22.1%) | -$38.50 M(+2.1%) |
| Sept 2022 | - | -$7.14 M(-37.4%) | -$37.69 M(-0.7%) |
| June 2022 | - | -$11.40 M(+1.4%) | -$37.95 M(+16.3%) |
| Mar 2022 | - | -$11.24 M(+42.1%) | -$32.63 M(+24.4%) |
| Dec 2021 | -$12.23 M(-49.3%) | - | - |
| Nov 2021 | - | -$7.91 M(+7.0%) | -$26.23 M(+9.9%) |
| Aug 2021 | -$24.15 M(+231.0%) | -$7.39 M(+21.4%) | -$23.88 M(+22.4%) |
| May 2021 | - | -$6.09 M(+25.8%) | -$19.50 M(+24.4%) |
| Feb 2021 | - | -$4.84 M(-12.9%) | -$15.68 M(+5.4%) |
| Dec 2020 | -$7.29 M(-37.9%) | - | - |
| Nov 2020 | - | -$5.56 M(+84.3%) | -$14.88 M(+26.6%) |
| Aug 2020 | -$11.75 M(-19.6%) | -$3.02 M(+32.8%) | -$11.75 M(+1.0%) |
| May 2020 | - | -$2.27 M(-43.7%) | -$11.63 M(-13.3%) |
| Feb 2020 | - | -$4.04 M(+66.1%) | -$13.41 M(+5.1%) |
| Nov 2019 | - | -$2.43 M(-16.0%) | -$12.76 M(-12.7%) |
| Aug 2019 | -$14.62 M(+8.2%) | -$2.89 M(-28.7%) | -$14.62 M(-5.8%) |
| May 2019 | - | -$4.06 M(+20.1%) | -$15.53 M(-1.7%) |
| Feb 2019 | - | -$3.38 M(-21.2%) | -$15.79 M(+3.2%) |
| Nov 2018 | - | -$4.29 M(+13.1%) | -$15.30 M(+13.2%) |
| Aug 2018 | -$13.52 M(+25.6%) | -$3.80 M(-12.2%) | -$13.52 M(+2.6%) |
| May 2018 | - | -$4.32 M(+49.5%) | -$13.18 M(+22.1%) |
| Feb 2018 | - | -$2.89 M(+15.3%) | -$10.79 M(-2.4%) |
| Nov 2017 | - | -$2.51 M(-27.3%) | -$11.06 M(+2.8%) |
| Aug 2017 | -$10.77 M(+7.6%) | -$3.45 M(+77.6%) | -$10.77 M(-3.7%) |
| May 2017 | - | -$1.94 M(-38.5%) | -$11.18 M(-0.3%) |
| Feb 2017 | - | -$3.16 M(+43.0%) | -$11.21 M(+14.0%) |
| Nov 2016 | - | -$2.21 M(-42.8%) | -$9.83 M(-1.6%) |
| Aug 2016 | -$10.01 M(+35.6%) | -$3.87 M(+96.1%) | -$9.99 M(+18.9%) |
| May 2016 | - | -$1.97 M(+10.6%) | -$8.40 M(+4.9%) |
| Feb 2016 | - | -$1.78 M(-24.8%) | -$8.02 M(+1.9%) |
| Nov 2015 | - | -$2.37 M(+4.1%) | -$7.87 M(+6.8%) |
| Aug 2015 | -$7.38 M | -$2.28 M(+44.0%) | -$7.37 M(+6.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| May 2015 | - | -$1.58 M(-3.2%) | -$6.94 M(-3.4%) |
| Feb 2015 | - | -$1.63 M(-12.8%) | -$7.18 M(+7.9%) |
| Nov 2014 | - | -$1.87 M(+1.5%) | -$6.66 M(+12.8%) |
| Aug 2014 | -$5.90 M(+37.2%) | -$1.85 M(+1.3%) | -$5.90 M(+12.3%) |
| May 2014 | - | -$1.82 M(+64.1%) | -$5.25 M(+12.3%) |
| Feb 2014 | - | -$1.11 M(-0.8%) | -$4.68 M(-1.7%) |
| Nov 2013 | - | -$1.12 M(-6.7%) | -$4.76 M(+10.8%) |
| Aug 2013 | -$4.30 M(+49.8%) | -$1.20 M(-3.9%) | -$4.30 M(+7.3%) |
| May 2013 | - | -$1.25 M(+4.8%) | -$4.01 M(+21.7%) |
| Feb 2013 | - | -$1.19 M(+81.4%) | -$3.29 M(+7.2%) |
| Nov 2012 | - | -$657.30 K(-27.7%) | -$3.07 M(+7.1%) |
| Aug 2012 | -$2.87 M(+86.5%) | -$909.00 K(+70.1%) | -$2.87 M(+4.5%) |
| May 2012 | - | -$534.40 K(-44.9%) | -$2.74 M(+57.9%) |
| Feb 2012 | - | -$970.20 K(+114.2%) | -$1.74 M(+24.2%) |
| Nov 2011 | - | -$452.90 K(-42.4%) | -$1.40 M(-9.0%) |
| Aug 2011 | -$1.54 M(-47.3%) | -$786.30 K(-266.7%) | -$1.54 M(-18.7%) |
| May 2011 | - | $471.80 K(-174.7%) | -$1.89 M(-40.1%) |
| Feb 2011 | - | -$631.70 K(+6.7%) | -$3.16 M(+8.6%) |
| Nov 2010 | - | -$592.00 K(-48.1%) | -$2.91 M(-0.3%) |
| Aug 2010 | -$2.92 M(+7.4%) | -$1.14 M(+43.8%) | -$2.92 M(+34.2%) |
| May 2010 | - | -$792.90 K(+107.8%) | -$2.17 M(+15.2%) |
| Feb 2010 | - | -$381.60 K(-36.5%) | -$1.88 M(-12.0%) |
| Nov 2009 | - | -$601.10 K(+51.6%) | -$2.14 M(-21.7%) |
| Aug 2009 | -$2.71 M(+1.9%) | -$396.40 K(-21.6%) | -$2.74 M(-20.5%) |
| May 2009 | - | -$505.60 K(-20.9%) | -$3.44 M(-8.8%) |
| Feb 2009 | - | -$638.90 K(-46.5%) | -$3.77 M(+8.8%) |
| Nov 2008 | - | -$1.19 M(+8.5%) | -$3.47 M(+31.7%) |
| Aug 2008 | -$2.66 M(-11.9%) | -$1.10 M(+31.2%) | -$2.63 M(-33.8%) |
| May 2008 | - | -$838.90 K(+151.8%) | -$3.98 M(+15.9%) |
| Feb 2008 | - | -$333.10 K(-7.6%) | -$3.43 M(+1.9%) |
| Nov 2007 | - | -$360.50 K(-85.3%) | -$3.37 M(+9.2%) |
| Aug 2007 | -$3.02 M(+632.4%) | -$2.44 M(+729.9%) | -$3.08 M(+236.1%) |
| May 2007 | - | -$294.60 K(+9.8%) | -$917.70 K(+22.4%) |
| Feb 2007 | - | -$268.30 K(+252.6%) | -$750.00 K(+55.2%) |
| Nov 2006 | - | -$76.10 K(-72.7%) | -$483.30 K(+17.2%) |
| Aug 2006 | -$412.90 K(+821.7%) | -$278.70 K(+119.6%) | -$412.20 K(+208.8%) |
| May 2006 | - | -$126.90 K(+7831.3%) | -$133.50 K(+1922.7%) |
| Feb 2006 | - | -$1600.00(-68.0%) | -$6600.00(+32.0%) |
| Nov 2005 | - | -$5000.00 | -$5000.00 |
| Aug 2005 | -$44.80 K | - | - |
FAQ
- What is Oramed Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Oramed Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals TTM EBITDA year-on-year change?
What is Oramed Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ORMP is $7.32 M
What is the all time high annual EBITDA for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $7.32 M
What is Oramed Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ORMP is -$3.04 M
What is the all time high quarterly EBITDA for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $14.56 M
What is Oramed Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ORMP quarterly earnings before interest, taxes, depreciation & amortization has changed by -$17.60 M (-120.86%)
What is Oramed Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ORMP is $24.86 M
What is the all time high TTM EBITDA for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $25.49 M
What is Oramed Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ORMP TTM earnings before interest, taxes, depreciation & amortization has changed by +$17.54 M (+239.54%)